About Advanz Pharmaceutical
Advanz Pharmaceutical is a Healthcare company based in Mississauga (Canada) founded in 1963, and was acquired by Nordic Capital in January 2021. Specialty generic and off-patent medicines are manufactured in various forms. Advanz Pharmaceutical has raised $13.49 million across 7 funding rounds from investors including Ontario Teachers' Pension Plan and Nordic Capital. Advanz Pharmaceutical has completed 2 acquisitions, including ADVANZ PHARMA and Pinnacle Biologics. Advanz Pharmaceutical offers products and services including Innovative Medicines, Specialty Generics, and Biosimilars. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Concordia International Corp.
Company details
Advanz Pharmaceutical was established in 1963 and is headquartered in Mississauga, Canada. Operations focus on the production of specialty generic and off-patent pharmaceuticals across multiple dosage forms. Therapeutic areas covered include cardiovascular, respiratory, gastrointestinal, antibiotics, antiviral, antifungal, hematological, and additional categories. In 2018, annual revenues reached 536 million, with net profit recorded at 1.5 billion.
- Headquarters Mississauga, Canada
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website advanzpharma.com
- Social LinkedIn
- Acquired by Nordic Capital (Jan 2021)
- Legal Name Concordia International Corp.
- Total Equity Funding$13.49M (USD)
in 7 rounds
- InvestorsOntario Teachers' Pension Plan
& 1 more
- Investments & AcquisitionsADVANZ PHARMA
& 1 more
- Acquired byNordic Capital
(Jan 2021)
Products & Services of Advanz Pharmaceutical
Advanz Pharmaceutical offers a comprehensive portfolio of products and services, including Innovative Medicines, Specialty Generics, and Biosimilars.
Treats conditions in hepatology and gastroenterology areas
Affordable alternatives for critical care treatments
Alternatives to original drugs for endocrinology needs
Funding Insights of Advanz Pharmaceutical
Advanz Pharmaceutical has successfully raised a total of $13.49M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.49M
- Total Rounds 7
- First Round $8.43M
(Mar 2007)
- Investors Count 2
All 7 funding rounds of Advanz Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | Post-IPO | – | – | ||
| Sep 2018 | $586.5M | Post-IPO | – | – | – |
| Oct 2016 | $350M | Debt – Conventional | – | – | – |
| Mar 2014 | $67.6M | Post-IPO | – | – | – |
| Dec 2013 | $5.06M | Post-IPO | – | – | – |
| Dec 2013 | $5.06M | Series A | – | – | – |
| Mar 2007 | $8.43M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Advanz Pharmaceutical
Advanz Pharmaceutical has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Ontario Teachers' Pension Plan and Nordic Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| nordiccapital.com | ||||
Pension funds focused on multiple sectors | 1990 | otpp.com | Toronto, Canada |
Investor details for Advanz Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Advanz Pharmaceutical
163 people are tracked at Advanz Pharmaceutical (81 in leadership, 82 in team).
| Name | Role | Group |
|---|---|---|
Maxine Ashby Fcipd | Vice President Global Human Resources | Leadership |
Steffen Wagner | Chief Executive Officer | Leadership |
Susanna El-Armale | Chief Corporate Development Officer | Leadership |
Fiona Huzarski | Chief People Officer | Leadership |
Andreas Stickler | Chief Financial Officer | Leadership |
Nowel Redder | Global QPPV - Director Patient Safety | Leadership |
Lewis Bell | Associate Director - Sales | Leadership |
Anaïs Lesimple | Associate Director Business Development | Leadership |
Nick Warwick | Chief Medical Officer | Leadership |
Karl Belk | Chief Operations Officer | Leadership |
Simon Tucker | Chief Commercial Officer International | Leadership |
Manish Arora | Commercial Finance Director | Leadership |
Will Fraser | Senior Talent Partner | Leadership |
Stephen Ferguson | Director - Quality Systems & QP | Leadership |
Angela Smart | Director, Global Medical Excellence And Operations | Leadership |
Amit Karande | Associate Director - Supplier Alliance Management | Leadership |
Dave McNamara | Vice President Of Sourcing, Procurement And Supplier Development | Leadership |
Carita Viru | Legal Director, Commercial Europe | Leadership |
Cyinthia Dcosta | Executive Assistant To Vice President -ma | Leadership |
Anke Niedernberg | Chief Transformation Officer | Leadership |
143 more people are available in the full profile.
Complete people profiles for Advanz Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Advanz Pharmaceutical
Advanz Pharmaceutical has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include ADVANZ PHARMA and Pinnacle Biologics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
ADVANZ PHARMA is engaged in providing specialty and rare disease medicines. | correvio.com | Vancouver, Canada | 1986 | Mar 2020 | $76M | |
Photodynamic therapies for cancers and rare diseases are developed. | pinnaclebiologics.com | Chicago, United States | 2007 | Dec 2013 | $58M |
Complete acquisition details for Advanz Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Advanz Pharmaceutical
7 dated milestones of Advanz Pharmaceutical across 61 years, from founding to its latest funding, stage changes and deals.
- Founded Advanz Pharmaceutical is founded.
- Funding First funding round of $8.4M.
- Acquisition Acquires Pinnacle Biologics.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires ADVANZ PHARMA.
- Exit Acquired by Nordic Capital.
- Funding Latest funding round, Post-IPO,.
Web traffic of Advanz Pharmaceutical
The website of Advanz Pharmaceutical (advanzpharma.com) receives about 7K visits a month and ranks #2,512,187 among all websites worldwide, #3,448 in Biotechnology and Pharmaceuticals.
- Monthly visits7K
▼ 17% vs previous month
- Unique visitors3.5K
per month
- Global rank#2,512,187
among all websites
- Category rank#3,448
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.9
- Average visit15 sec
- DevicesDesktop 46% · Mobile 54%
Websites whose visitors overlap most with Advanz Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mangalamdrugs.com | 100% | 9.9K | #1,747,627 | View details | |
| rusanpharma.com | 96% | 4K | #3,386,749 | View details | |
| calyxindia.com | 95% | 1K | #7,901,342 | View details | |
| pharmaguddu.com | 93% | #1,114,765 | View details | ||
| ajantapharma.com | 92% | 20.1K | #1,412,069 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Advanz Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Advanz Pharmaceutical
Complete news archive for Advanz Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Advanz Pharmaceutical
Advanz Pharmaceutical was founded in 1963 and raised its 1st funding round 44 years after it was founded.
Advanz Pharmaceutical is headquartered in Mississauga, Canada. It is registered at Mississauga, Ontario, Canada.
Advanz Pharmaceutical is a funded company, having raised a total of $13.49M across 7 funding rounds to date. The company's 1st funding round was a Series A of $8.43M, raised on Mar 2007.
Advanz Pharmaceutical was established in 1963 and is headquartered in Mississauga, Canada. Operations focus on the production of specialty generic and off-patent pharmaceuticals across multiple dosage forms. Therapeutic areas covered include cardiovascular, respiratory, gastrointestinal, antibiotics, antiviral, antifungal, hematological, and additional categories. In 2018, annual revenues reached 536 million, with net profit recorded at 1.5 billion.
Advanz Pharmaceutical offers Innovative Medicines, Specialty Generics, and Biosimilars.
Advanz Pharmaceutical has made 2 acquisitions, including ADVANZ PHARMA, and Pinnacle Biologics.
Advanz Pharmaceutical has 2 investors. Key investors include Ontario Teachers' Pension Plan, and Nordic Capital.
Advanz Pharmaceutical operates through Concordia International Corp..
Yes. Advanz Pharmaceutical was acquired by Nordic Capital in January 2021.